Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

18.43 -1.02 (-5.27%)
Streaming Delayed Price Updated: 10:11 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
What's Driving the Market Sentiment Around ADMA Biologics?
Via Benzinga
ADMA BIOLOGICS INC (NASDAQ:ADMA) is showing good growth, while it is not too expensive.
NASDAQ:ADMA is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
What's Driving the Market Sentiment Around ADMA Biologics?
Via Benzinga
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook
CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024. 
Via Stocktwits
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Peering Into ADMA Biologics's Recent Short Interest
Via Benzinga
How Is The Market Feeling About ADMA Biologics?
Via Benzinga
Looking Into ADMA Biologics's Recent Short Interest
Via Benzinga
Earnings Scheduled For March 3, 2025
Via Benzinga
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter. 
Via Stocktwits
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025. 
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86. 
Via Investor's Business Daily
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
SpringWorks Therapeutics Stock Gets A RS Rating Lift
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76. 
Via Investor's Business Daily
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
From ADMA Biologics, Inc.
Via GlobeNewswire
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Via ACCESSWIRE
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
Via ACCESSWIRE
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
While growth is established for NASDAQ:ADMA, the stock's valuation remains reasonable.
For those who appreciate growth without the sticker shock, NASDAQ:ADMA is worth considering. 
Via Chartmill
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation
From Kirby McInerney LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.